Multivariate statistics

New IDBS Polar data science capabilities democratize access to AI/ML-powered insights to accelerate BioPharma process optimization

Retrieved on: 
Thursday, February 23, 2023
MVA, Therapure BioPharma Inc, Statistics, Doe, Biopharmaceutical, Technology transfer, Immortalised cell line, IDBS, Multivariate statistics, Design of experiments, Polar, Medical imaging

WOKING, United Kingdom, Feb. 23, 2023 /PRNewswire/ -- IDBS announces the launch of new data science capabilities for its Polar platform to accelerate BioPharma process optimization.

Key Points: 
  • WOKING, United Kingdom, Feb. 23, 2023 /PRNewswire/ -- IDBS announces the launch of new data science capabilities for its Polar platform to accelerate BioPharma process optimization.
  • Accessing meaningful insights from process and quality data across the BioPharmaceutical lifecycle is critical to accelerating time to market of life-changing therapies.
  • IDBS Polar unlocks the value of data by providing integrated digital workflows, eliminating data silos and delivering a high-quality, contextualized data backbone.
  • Democratizing access to process insight enables BioPharma organizations to efficiently focus resources on the critical areas for quality and performance to accelerate process development, regulatory filings and technology transfer."

New IDBS Polar data science capabilities democratize access to AI/ML-powered insights to accelerate BioPharma process optimization

Retrieved on: 
Thursday, February 23, 2023
MVA, Therapure BioPharma Inc, Statistics, Doe, Biopharmaceutical, Technology transfer, Immortalised cell line, IDBS, Multivariate statistics, Design of experiments, Polar, Medical imaging

WOKING, United Kingdom, Feb. 23, 2023 /PRNewswire/ -- IDBS announces the launch of new data science capabilities for its Polar platform to accelerate BioPharma process optimization.

Key Points: 
  • WOKING, United Kingdom, Feb. 23, 2023 /PRNewswire/ -- IDBS announces the launch of new data science capabilities for its Polar platform to accelerate BioPharma process optimization.
  • Accessing meaningful insights from process and quality data across the BioPharmaceutical lifecycle is critical to accelerating time to market of life-changing therapies.
  • IDBS Polar unlocks the value of data by providing integrated digital workflows, eliminating data silos and delivering a high-quality, contextualized data backbone.
  • Democratizing access to process insight enables BioPharma organizations to efficiently focus resources on the critical areas for quality and performance to accelerate process development, regulatory filings and technology transfer."

Castle Biosciences Presents New Data Demonstrating the Clinical Utility and Value of DecisionDx®-SCC in Moderately and Poorly Differentiated Cutaneous Squamous Cell Carcinoma Tumors

Retrieved on: 
Tuesday, November 15, 2022
Oncology, Health, Research, Pharmaceutical, Science, Biotechnology, Uveal melanoma, Squamous cell carcinoma, Lymph, Head, American Joint Committee on Cancer, Uncertainty, Survival, Atopic dermatitis, Risk, Neck, Patient, ASDP, Multivariate statistics, Neoplasm, JAMA, Society, Journal of the American Academy of Dermatology, Health, Skin, COVID-19, CSCC, BWH, Risk assessment, Comparison, Metastasis, Hospital, Publication, Pharmaceutical industry, Medical imaging, Medical device, Wood drying, Brigham

Overall, these data demonstrate how DecisionDx-SCC can significantly stratify the risk of metastasis in high-risk cSCC patients with an ambiguous tumor differentiation status.

Key Points: 
  • Overall, these data demonstrate how DecisionDx-SCC can significantly stratify the risk of metastasis in high-risk cSCC patients with an ambiguous tumor differentiation status.
  • Subjective pathology variability in the histologic grading of cSCC tumors is an important clinical issue, particularly when comparing moderately differentiated tumors.
  • A single clinicopathologic risk factor, including a cSCC tumors differentiation status, can affect staging and thereby escalate or deescalate patient treatment plans, commented Estrada.
  • JAMA Dermatol 154:175, 2018
    Prezzano JC, Scott GA, Lambert Smith F, et al: Concordance of Squamous Cell Carcinoma Histologic Grading Among Dermatopathologists and Mohs Surgeons.

Machine Learning Pioneer Dynam.AI Hires AI Founder Craig Parfitt as Chief Technology Officer

Retrieved on: 
Friday, July 8, 2022
Foot-pound (energy), Artificial intelligence, Pattern recognition, Mechanical, ML, University, Strategic Command (United Kingdom), NexTier Bank, Research, CEO, Chubb Limited, HSBC, Lazard, Hostess, National Health Service, Mechanical engineering, 3D, Lloyds Banking Group, IISc Guidance, Control and Decision Systems Laboratory, Multivariate statistics, UK Border Agency, Business development, SAN, BAE Systems, NHS, Technology, Organization, Machine learning, Solution, AI, Chubb, Biomedical engineering, Government, GFT, Gener8tor, Medical device, Management, Parfitt, Neuroscience, Atlantic Ocean

SAN DIEGO, July 8, 2022 /PRNewswire-PRWeb/ -- Dynam.AI, an artificial intelligence (AI) software development firm best known for full stack AI innovation, today announced that Craig Parfitt has joined the company's executive team as Chief Technology Officer. Mr. Parfitt is a data, analytics and artificial intelligence expert with deep ties in the field of AI and machine learning. An AI technology founder, Parfitt has spent the past two decades developing these capabilities for a number of organizations working in consulting, private industry and government.

Key Points: 
  • SAN DIEGO, July 8, 2022 /PRNewswire-PRWeb/ -- Dynam.AI, an artificial intelligence (AI) software development firm best known for full stack AI innovation, today announced that Craig Parfitt has joined the company's executive team as Chief Technology Officer.
  • Mr. Parfitt is a data, analytics and artificial intelligence expert with deep ties in the field of AI and machine learning.
  • An AI technology founder, Parfitt has spent the past two decades developing these capabilities for a number of organizations working in consulting, private industry and government.
  • Mr. Parfitt is a technology founder who started an AI led consulting firm and developed a data-driven, intelligent solution for the insurance industry.

New Study in Journal of Pharmaceutical Analysis Reveals Influence of Host Plant on Medicinal Qualities of Mistletoe

Retrieved on: 
Thursday, June 9, 2022
Parasitic plant, Research, Herbal medicine, Temperature, Forest, Arthralgia, Multivariate statistics, Motivation, Central Statistics Office (India), Metabolomics, Shenyang Pharmaceutical University, Mistletoe, Soil, Plant, Photosynthesis, Water resources, Medicinal plants, Dietary supplement

One such plant with many medicinal benefits is Viscum coloratum (V. coloratum), commonly known as mistletoe.

Key Points: 
  • One such plant with many medicinal benefits is Viscum coloratum (V. coloratum), commonly known as mistletoe.
  • Hemiparasitic plants, such as V. coloratum, obtain their nutrition from their host plants, as well as through photosynthesis.
  • At the same time, research has also shown that the metabolites and bioactivities of hemiparasitic plants are influenced by their "host plants."
  • This indicates that the host plant and environmental factors could affect the medicinal quality of hemiparasitic plants.

World’s First External Independent Randomized Controlled Trial of Artificial Intelligence Demonstrates More Accurate Colonoscopy Screening and Surveillance Utilizing Wision AI’s Technology Compared to the Standard of Care

Retrieved on: 
Wednesday, September 29, 2021
X, Clinical Gastroenterology and Hepatology, Veni, vidi, vici, Mathematics, CRC, Patient, Adenoma, Deep learning, SSL, CT, Randomized controlled trial, Isabella Tree, DNA, Data, Beth Israel Deaconess Medical Center, AMR, Population, Physician, MD, Hepatology, Hospital, AI, APC, Sessile serrated lesion, Gastroenterology, Colonoscopy, ADR, RCT, Technology, PMR, Algorithm, Intelligence, Polyp, Cade, Colorectal cancer, Multivariate statistics, GLOBE, Google Images, Medical device, Medical imaging, Phosphorus, Typesetting

SHANGHAI, China, Sept. 29, 2021 (GLOBE NEWSWIRE) -- Wision AI, a leader in developing computer-aided diagnostic algorithms and real-time systems to improve the accuracy and effectiveness of diagnostic imaging, today announced the publication of data demonstrating positive results and competitive advantages of using its artificial intelligence computer-aided polyp detection (CADe) system during colorectal cancer screening in a U.S. patient population. In this world’s first external independent randomized controlled trial (RCT) of AI in the medical field conducted in the United States (NCT03925337), 232 patients were enrolled for screening and surveillance colonoscopy in four leading U.S. academic institutions. Results indicated that the Wision AI‘s CADe device, EndoScreener, significantly reduced the adenoma miss rate (31.25% vs. 20.12%, p=0.0247) and increased adenoma detected per colonoscopy (0.90 vs. 1.19, p=0.0323). The trial data have been published in Clinical Gastroenterology & Hepatology.i

Key Points: 
  • In this worlds first external independent randomized controlled trial (RCT) of AI in the medical field conducted in the United States (NCT03925337), 232 patients were enrolled for screening and surveillance colonoscopy in four leading U.S. academic institutions.
  • This is the worlds first randomized controlled trial of AI technology to conclusively show generalizability by independent, external validation.
  • Patients in the trial were randomly assigned to groups that received either AI-assisted colonoscopy or routine colonoscopy, followed immediately by the other procedure.
  • Patients were randomized to either CADe (n=113) or HDWL colonoscopy (n=110) first, after which they immediately underwent colonoscopy using the other method.